Representatives from the following organizations participated in the first CCRP meeting: Pan American Health Organization (PAHO); Department for the Control of Neglected Tropical Diseases, WHO; Ministries of Health and National Control Programmes of high burden endemic countries (Argentina, Bolivia, Brazil, Mexico); Hospital de Niños Ricardo Gutiérrez, Argentina; Instituto Nacional de Parasitología Dr. M Fatala Chabén, Argentina; Hospital de Niños de Jujuy, Argentina; Hospital Público Materno Infantil – Salta, Argentina; Centro de Chagas y Patologia Regional, Santiago del Estero, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; Instituto Oswaldo Cruz, Brazil; Instituto de Pesquisa Evandro Chagas–Fiocruz, Brazil; Centro de Pesquisas René Rachou–Fiocruz, Brazil; Universidad Mayor de San Simon– Platform of Integral Care for Patients with Chagas Disease, Bolivia; CRESIB - Hospital Clinic Barcelona, Spain; Médecins Sans Frontières; Institut de Recherche pour le Développement, France; Eisai, Japan.

Objectives: To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The CCRP aims to facilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it will identify and review priority needs, work towards standardization of methodology to assess drug efficacy to treat T. cruzi infection, review alternatives for using current drugs approved (new schemes, doses, combination) and special scenarios (resistance).